News | February 22, 2023
Merck updates on Phase 3 MOVe-AHEAD trial evaluating Lagevrio
The safety profile of LAGEVRIO in this trial was generally consistent with that observed in previously reported clinical studies
The safety profile of LAGEVRIO in this trial was generally consistent with that observed in previously reported clinical studies
FDA also accepts a separate supplemental application to extend prophylaxis with PREVYMIS to 200 days in certain HSCT recipients
Approval marks fifth indication for KEYTRUDA-based regimens in NSCLC and 34th indication for KEYTRUDA in the US
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial
Presentations include new data on investigational medicines – favezelimab (MK-4280), zilovertamab vedotin (MK-2140) and nemtabrutinib – as well as KEYTRUDA (pembrolizumab) in multiple blood cancers
Acquisition expands Merck’s growing hematology portfolio
Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint
The TBDA is a collaboration established among biopharmaceutical companies, research organizations and universities to accelerate the discovery and development of novel therapeutic candidates against TB.
Sotatercept demonstrated significant improvement in exercise capacity and key secondary outcome measures compared to placebo when added to background therapy
Subscribe To Our Newsletter & Stay Updated
